Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al.
Molecular Psychiatry February 17, 2022 Guang Chen, G. Mannens, Marlies de Boeck et al. 14 citations
An open-label study of (R)-ketamine for depression cannot establish efficacy due to expectancy biases and large placebo effects, even in treatment-resistant patients. One patient showed clinically meaningful dissociation. The antidepressant efficacy and optimal dose of (R)-ketamine must be determined in randomized controlled trials. A study in healthy volunteers found that (R)-ketamine and (S)-ketamine produced similar frequency and character of dissociative and other central nervous system adverse effects when compared at doses equipotent for NMDAR antagonism.